REGENXBIO Inc. $RGNX Shares Sold by Voss Capital LP

Voss Capital LP reduced its stake in shares of REGENXBIO Inc. (NASDAQ:RGNX) by 13.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 500,000 shares of the biotechnology company’s stock after selling 75,000 shares during the period. Voss Capital LP’s holdings in REGENXBIO were worth $4,825,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the stock. CANADA LIFE ASSURANCE Co increased its position in REGENXBIO by 33.9% during the third quarter. CANADA LIFE ASSURANCE Co now owns 14,510 shares of the biotechnology company’s stock worth $143,000 after purchasing an additional 3,671 shares during the last quarter. Mariner LLC boosted its holdings in shares of REGENXBIO by 150.4% in the 3rd quarter. Mariner LLC now owns 32,306 shares of the biotechnology company’s stock valued at $312,000 after purchasing an additional 19,402 shares during the last quarter. Mercer Global Advisors Inc. ADV purchased a new stake in shares of REGENXBIO during the 3rd quarter valued at $192,000. Invenomic Capital Management LP purchased a new stake in shares of REGENXBIO during the 3rd quarter valued at $4,120,000. Finally, Brevan Howard Capital Management LP acquired a new stake in shares of REGENXBIO during the 3rd quarter worth $158,000. 88.08% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages recently weighed in on RGNX. Chardan Capital cut their target price on REGENXBIO from $52.00 to $50.00 and set a “buy” rating on the stock in a research report on Tuesday, February 10th. UBS Group restated an “overweight” rating and set a $18.00 price target on shares of REGENXBIO in a research note on Tuesday, February 10th. Stifel Nicolaus raised their price objective on REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, December 19th. Barclays began coverage on REGENXBIO in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $37.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus price target of $27.50.

REGENXBIO Trading Down 1.7%

Shares of RGNX stock opened at $8.64 on Wednesday. The company has a market cap of $445.91 million, a PE ratio of -2.30 and a beta of 1.08. The company’s fifty day simple moving average is $10.80 and its 200-day simple moving average is $11.46. REGENXBIO Inc. has a 52 week low of $5.03 and a 52 week high of $16.19.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, March 5th. The biotechnology company reported ($1.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.29). REGENXBIO had a negative return on equity of 103.12% and a negative net margin of 113.75%.The business had revenue of $30.34 million for the quarter, compared to analysts’ expectations of $45.48 million. Equities research analysts expect that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Insider Activity at REGENXBIO

In other REGENXBIO news, insider Steve Pakola sold 5,124 shares of the business’s stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $10.35, for a total transaction of $53,033.40. Following the transaction, the insider owned 247,926 shares in the company, valued at $2,566,034.10. The trade was a 2.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.79% of the stock is currently owned by corporate insiders.

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.